

Hk Kk E lkn eanl Ca n L d'and e o l E lkn eo Hk Kk L d' a eno e on o e
on o o ankn le o , a eno e e o a on a o a l a l o o e o e anl e e d' l a n
a a o e e o an o o o e e a n o o n ean le on e o e o an a o e on o o
ankn le o .



上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(on o l d o an n o o a d' n e o e' R e l o C n a d' a)
(Stock Code: 02196)

2013 THIRD QUARTERLY REPORT

T l l v r t t l l t t R l 13.09(2) d' R l 13.10B t R l G l l t
L t l S t t T St A E H K L t d' d' t I d' I t
P l l P t I A t S t l F t O d' (C t 571 t L v H
K l).

T l l v r t t l l t l t 2013 S l F l P l l (G l l) C .
Ltd.* (t "Company", t t v t t l l t l t "Group"). T l l t
t l l d' v t t PRC A l t St d' B l E t l
t l l t l l .

B O d' t B d'
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Ca an

S l l t P l l' R l l C l
30 O t 2013

A a e d' eo ankn le o , e e e e d' eo a e . C a l and . a o E n ; enon-e e e
d' eo a e . Go Ga n an , . an l n n , . an Go o , . an n an and . K n E n ; and
e n d e o d' a non-e e e d' eo a e . H n Jon , D . an e on , . L an- A d an D d' and .
G o H n .

* Fo d' a on o e on

§3 SIGNIFICANT EVENTS

[illegible]
$$\sqrt{A_{\ell}} \cdot \mathbf{1}_{\ell} \leq \mathbf{1} \leq \sqrt{N} \cdot \mathbf{t} \cdot A_{\ell} \cdot \mathbf{1}_{\ell}$$

t: , **C:** RMB

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
Current assets	2,485,783,000.50	4,972,524,758.70	-50%	Mainly due to the decrease in prepayments in 2013
Intangible assets	1,316,781,579.78	907,307,576.06	45%	Mainly due to the increase in goodwill in 2013
Investment properties	7,615,057.77	17,674,707.55	-57%	Mainly due to the decrease in investment properties in 2013
Investments in subsidiaries	2,368,367,750.12	1,752,799,860.87	35%	Mainly due to the increase in investments in subsidiaries in 2013
Deferred tax assets	42,946,124.18	29,475,413.33	46%	Mainly due to the increase in R&D tax credits in 2013
Goodwill	2,710,407,586.05	1,661,770,763.96	63%	Mainly due to the increase in goodwill in 2013
Other non-current assets	236,069,350.21	100,654,101.39	135%	Mainly due to the increase in other non-current assets in 2013
Deferred tax liabilities	72,033,067.63	31,482,514.80	129%	Mainly due to the increase in deferred tax liabilities in 2013
Subsidiaries' equity	1,199,559,074.08	519,422,250.00	131%	Mainly due to the increase in subsidiaries' equity in 2013
Deferred tax liabilities	12,240,519.57	4,725,748.28	159%	Mainly due to the increase in deferred tax liabilities in 2013
Other non-current liabilities	33,196,473.53	526,384,431.15	-94%	Mainly due to the decrease in other non-current liabilities in 2013

§4 APPENDICES

4.1

Consolidated balance sheet

30 e e e 2013

P : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: _____ Currencies: RMB T: _____ t: _____ t: _____

[illegible]

Consolidated balance sheet (Continued)

30 e e e 2013

[illegible]

Consolidated balance sheet (Continued)

30 e e e 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
P	2,240,462,364.00	2,240,462,364.00
C	4,396,998,107.25	4,287,287,930.01
L		
S		
S	1,338,476,598.49	1,338,476,598.49
G		
	6,621,610,997.36	5,703,028,462.15
F	-4,289,492.31	-10,462,767.38
T	14,593,258,574.79	13,558,792,587.27
M	1,889,445,595.04	1,745,855,848.86
T	16,482,704,169.83	15,304,648,436.13
T	27,589,580,696.34	25,507,140,466.01

L, l R, r t t t
C : C Q,

C F l O :
H, J

D t t A, t,
D t t: J

Balance sheet of the Parent Company

30 e e e 2013

P : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

t: , C : RMB T , t: , t

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C	967,810,425.06	2,804,108,583.37
F		
B ll		
T		
P		
I t t l	112,185,785.22	98,972,778.68
D	24,240,000.00	
O t l	1,207,151,982.57	941,562,545.17
I t	517,042.01	516,409.53
N - t t t , w t		
O t t t	280,000,000.00	250,000,000.00
T t l t t	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
A l l - - l t		
H t - t t t t		
L t l		
L t t t t t	5,471,340,934.74	4,173,763,622.82
I t t t t		
F t	20,153,012.47	20,815,349.96
C t t		
P j t l		
D l t		
P t l t		
O l t		
I t l t	3,215,662.67	3,496,198.41
D l t t		
G , w ll		
L t t t t		
D t t t		
O t t t t t	4,470,831,299.40	4,035,133,683.09
T t l - t t	9,965,540,909.28	8,233,208,854.28
T t l t	12,557,446,144.14	12,328,369,171.03

Balance sheet of the Parent Company (Continued)

30 e e e 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Short-term bank loans		
Financial liabilities at amortized cost		
Bill payables		
Trade payables		
Receivables from related parties		
Other payables	26,138,331.81	29,108,232.08
Trade receivables	16,833,088.84	5,188,721.77
Liabilities from financial instruments	155,509,208.37	152,405,396.96
Deferred income		
Other	554,584,851.12	46,800,203.98
Non-current liabilities	360,000,000.00	355,000,000.00
Other		499,375,000.00
Total	1,113,065,480.14	1,087,877,554.79
Non-current liabilities:		
Long-term bank loans	125,000,000.00	165,000,000.00
Bonds	4,070,832,033.25	4,063,347,254.54
Long-term payables		
Subordinated liabilities		
Accounts payable		
Deferred income		
Other	2,275,000.00	2,500,000.00
Total	4,198,107,033.25	4,230,847,254.54
Total	5,311,172,513.39	5,318,724,809.33
Equity attributable to the owners (or equity attributable to shareholders):		
Preferred shares (non-cumulative)	2,240,462,364.00	2,240,462,364.00
Common shares	3,754,014,307.53	3,755,009,519.04
Liabilities		
Subordinated liabilities		
Subordinated liabilities	305,635,420.68	305,635,420.68
Guaranteed liabilities		
Other	946,161,538.54	708,537,057.98
Total	7,246,273,630.75	7,009,644,361.70
Total	12,557,446,144.14	12,328,369,171.03

$$L, 1R, \dots, t, \dots, t$$

$$C, \dots, C, Q, \dots, t$$

C F 10 :
H J

D. t. t. A. r. t. r.
D. t. t. J.

4.2

Consolidated Income Statement

Data — e e e 2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB T

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Total	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income before income tax	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income tax				
Expense				
F				
II. Total	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
Income before income tax	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
Income tax				
F				
P				
C				
N				
P				
A				
B	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
S	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
A	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
F	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
A	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
Profit before income tax				
Profit before income tax ("–")	–548,949.75	–4,627,534.57	39,511,717.28	–14,636,854.56
Income tax ("–")	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
Income before income tax				
Income before income tax	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
F ("–")				
III. Income before income tax ("–")	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
Profit before income tax	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
L	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
Income before income tax	260,198.27	–243,201.72	979,886.77	946,040.98

Income Statement of the Parent Company

Annals — e e e 2013

P : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB T: t: t

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Other				
Losses				
Benefits				
Selling				
Administrative	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
Financial	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
Assets				
Provisions				
Income taxes (“-” in the amount)	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
Income taxes: Government	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. Other (“-” in the amount)	-34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
Provisions	76,900.00	234,093.38	236,049.11	734,093.38
Losses		-570,000.00	2,514,544.42	860,000.00
Income taxes: Local			5,725.77	
III. Total (“-” in the amount)	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Losses				
I. Net (“-” in the amount)	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Earnings				
(1)				
(2)				
I. Other			51,779.40	27,699,470.25
II. Total	-34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

L, I R, t t t C F I O : D t t A t, C : C Q H J D t t J

4.3

Consolidated Statement of Cash Flow

Ann. - e.e.e. 2013

[illegible]

Consolidated Statement of Cash Flow (Continued)

December 31, 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
II. Cash flow generated from investing activities (Continued):		
Cash paid for the acquisition of subsidiaries and businesses, net of cash acquired	711,664,658.89	839,693,736.40
Cash paid for the acquisition of intangible assets	251,949,461.45	734,761,521.45
Net cash paid for the acquisition of subsidiaries and businesses, net of cash acquired and intangible assets		
Net cash paid for the acquisition of intangible assets	2,011,879,515.78	
Other cash paid for investing activities	100,020,349.23	9,072,797.31
Subsidiaries and businesses acquired, net of cash acquired	3,075,513,985.35	1,583,528,055.16
Net cash paid for the acquisition of subsidiaries and businesses, net of cash acquired and intangible assets	-1,757,461,995.58	-368,977,652.38
III. Cash flow generated from financing activities:		
Cash received from the issuance of shares	2,088,710.98	761,199.00
Interest received	2,088,710.98	761,199.00
Cash received from the issuance of debt	1,302,361,982.24	1,022,152,808.76
Cash received from the issuance of equity		1,486,950,000.00
Other cash received from financing activities	329,448,475.13	262,541,891.46
Subsidiaries and businesses acquired, net of cash acquired	1,633,899,168.35	2,772,405,899.22
Cash paid for the acquisition of subsidiaries and businesses, net of cash acquired	1,221,891,677.53	2,628,044,486.20
Cash paid for the acquisition of intangible assets	950,844,046.86	601,916,917.03
Interest paid	702,264,204.84	366,813,171.49
Other cash paid for financing activities	48,488,630.70	101,408,014.93
Subsidiaries and businesses acquired, net of cash acquired	2,221,224,355.09	3,331,369,418.16
Net cash paid for the acquisition of subsidiaries and businesses, net of cash acquired and intangible assets	-587,325,186.74	-558,963,518.94
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-25,426,268.76	-4,569,909.53
V. Net increase of cash and cash equivalents	-1,902,809,425.34	-517,020,589.16
Plus: Opening balance of cash and cash equivalents	4,171,574,742.12	2,428,219,484.36
VI. Closing balance of cash and cash equivalents	2,268,765,316.78	1,911,198,895.20

L, I R, t t t
 C : C Q,

C F I O :
 H, J

D t t A, t,
 D t t: J

Statement of Cash Flow of the Parent Company

du a — e e e 2013

P : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: _____ C: _____ : RMB T: _____, q_t: _____, q_t q_t

[illegible]

Statement of Cash Flow of the Parent Company (Continued)

December 31, 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
III. Cash flow generated from financing activities:		
Cash and cash equivalents		
Cash and cash equivalents	255,115,078.77	
Cash and cash equivalents		1,486,950,000.00
Other	1,904,031,173.98	4,295,169,165.49
Subtotal	2,159,146,252.75	5,782,119,165.49
Cash and cash equivalents	790,115,078.77	454,000,000.00
Cash and cash equivalents	674,744,025.09	302,177,196.32
Other	2,109,471,293.35	5,478,222,986.00
Subtotal	3,574,330,397.21	6,234,400,182.32
Net increase of cash and cash equivalents	-1,415,184,144.46	-452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-22,851,531.32	
V. Net increase of cash and cash equivalents	-1,198,160,658.31	-9,857,758.83
Pl: O	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

L, I R, t t
C : C Q

C F I O :
H J

D t t A t,
D t t: J